Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
7th US Indication For The JAK Inhibitor, 2nd In IBD
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.
